Q-omics provides the consensus-scored TTLL1 profile across patient tissues and cancer cell-line models. TTLL1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TTLL1 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, TTLL1 RNA expression shows 19,001 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight HNSC, THCA, and ACC as cancer lineages where TTLL1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TTLL1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TTLL1 survival associations across molecular data types. TTLL1 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (5) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TTLL1 RNA expression–survival associations across cancer types. High TTLL1 expression shows unfavorable associations in LIHC and ACC, but favorable associations in HNSC, UCEC, ESCA and KIRP. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for TTLL1 RNA expression.
This table summarizes TTLL1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 2. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for TTLL1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TTLL1 shows lower tumor expression in THCA, KIRC and KICH and higher tumor expression in LIHC, CHOL and COAD. The THCA box plot shows higher TTLL1 RNA expression in normal versus tumor tissue (log2 FC = −0.801, t-test p < 0.001).
This table shows molecular features associated with TTLL1 in patient tissues and cancer cell lines. In patient samples, TTLL1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TTLL1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
